Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study

Hans Ibsen*, Kristian Wachtell, Michael H. Olsen, Knut Borch-Johnsen, Lars H. Lindholm, Carl Erik Mogensen, Björn Dahlöf

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstract

    Studies have shown that albuminuria is associated with increased risk for cardiovascular events. We tested the relationship between albuminuria (UACR) and cardiovascular risk in 8206 hypertensive patients with left ventricular hypertrophy included in the LIFE Study. Follow-up was 39,122 patient years. The risk for the primary composite cardiovascular end point increases continuously from the lowest to the highest decile of baseline UACR. No specific threshold could be identified. In conclusion, albuminuria predicts the outcome in the LIFE Study. The risk for cardiovascular morbidity and mortality among hypertensive patients with left ventricular hypertrophy increases at much lower UACR than has been reported in diabetic patients.

    OriginalsprogEngelsk
    Sider (fra-til)S56-S58
    TidsskriftKidney International, Supplement
    Vol/bind66
    Udgave nummer92
    DOI
    StatusUdgivet - 1 nov. 2004

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study' indeholder.

    Citationsformater